27 Oct 2023 --- DermBiont, a clinical-stage biotechnology company, has announced a US$35.2 million Series B financing, combining a US$27.1 million Series B first close and US$8.1 million in converting notes. The company is advancing targeted topical therapeutics for the treatment of dermatological indications. The proceeds will be used to further two drugs in development, SM-020, a topical AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs) and SM-030, a topical PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation skin disorders.
